about
Challenges of clinical trial design for targeted agents against pediatric leukemias.Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target.Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737.Interaction between invariant NKT cells and myeloid-derived suppressor cells in cancer patients: evidence and therapeutic opportunities.Adjunctive Treatment in Juvenile Nasopharyngeal Angiofibroma: How Should We Approach Recurrence?Molecular basis and current strategies of therapeutic arginine depletion for cancer.The development of targeted new agents to improve the outcome for children with leukemia.Neuroblastoma arginine addiction subverts the anticancer immune response.Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity.Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment.Arginine auxotrophic gene signature in paediatric sarcomas and brain tumours provides a viable target for arginine depletion therapies.TB-12ARGININE AUXOTROPHY IN PAEDIATRIC CNS TUMOURS: THE RATIONALE FOR THERAPEUTIC ARGININE DEPLETION AS A NOVEL ANTI-CANCER THERAPY.Enteroviral Encephalitis in a Child With CNS Relapse of Burkitt Leukemia Treated With Rituximab.The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated-recombinant arginase I BCT-100.Tumour-derived GM-CSF promotes granulocyte immunosuppression in mesothelioma patients.Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma.Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemiaMacrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in NeuroblastomaHemophagocytic Lymphohistiocytosis Associated With 2 Cases of Pediatric Lymphocyte-depleted Classic Hodgkin LymphomaCombination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid LeukemiaMDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancersTargeting the arginine metabolic brake enhances immunotherapy for leukaemia
P50
Q34839887-C2DF9791-28D6-4D5B-89BC-785A4418D615Q35561304-DBB58AE3-6CFB-49A8-8463-CFC83A868201Q37877741-51E50F03-552D-4885-8C9A-E24ACBF9A6C7Q38021913-F9688410-35DD-4E01-9406-A2F1FFF46041Q38747292-BE91F36B-CFD5-4A0D-A604-9A2A5F31CB07Q38749541-A3112A90-E38A-4CBD-8A74-E60BF1444F85Q38964974-727EFDE1-529B-4F11-AEDE-A03C5AFB266AQ39279665-5653BD81-145F-4E88-A77C-6BD524BC9EC1Q41686071-B1E69138-C1F2-48E7-99A2-15D9A626722FQ41873361-AA727ACD-1223-46D3-A018-05EA81D5A3E8Q42362675-25742C5E-C253-4D49-B59E-A19080681042Q46359267-6145A30C-E6D9-450F-8328-7D8851C3AED9Q47556669-715627C9-691F-47A0-B515-F829E67CEC1AQ48249089-FEC479EB-0422-421C-8CC7-9F2390CA2549Q52618088-72B17BDE-796D-4158-BBDA-37385A8DCC60Q55260248-3D66B65E-9C58-40B3-8039-CC1959898B2AQ61718329-7AFE260D-3B14-4023-A72D-2871AE4861CEQ61917630-6434E7D2-6EE9-4721-B431-2F1EABEB89FFQ90848273-3F341E8B-767D-4B32-B6FD-9CE5D06223C4Q91088695-EB5368A9-7955-49C2-A94E-D542A9B27F12Q92963506-1BE3B659-9E20-4C8B-A6FC-CD6549712FAAQ93369019-8FB2BD05-971B-451C-AC9D-29176ED8E3AB
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Francis Jay Mussai
@ast
Francis Jay Mussai
@en
Francis Jay Mussai
@es
Francis Jay Mussai
@nl
Francis Jay Mussai
@sl
type
label
Francis Jay Mussai
@ast
Francis Jay Mussai
@en
Francis Jay Mussai
@es
Francis Jay Mussai
@nl
Francis Jay Mussai
@sl
prefLabel
Francis Jay Mussai
@ast
Francis Jay Mussai
@en
Francis Jay Mussai
@es
Francis Jay Mussai
@nl
Francis Jay Mussai
@sl
P106
P31
P496
0000-0003-3342-0047